EE294 Cost-Substitution and Hospital Diagnosis-Related Group (DRG) Performance Impact Analysis of Infliximab Biosimilar Adoption in Moderate-to-Severe Crohn's Disease Patients in China
Abstract
Authors
Shuting Chen Yongjia Zhuo Yue Gao Jianfang Jiang Jianwei Xuan Qian Cao